PharmacoEconomics

New Anticoagulants for the Prevention of Deep Venous Thrombosis: Time to Consider Cost Effectiveness?
pp. 793-795(3)
Authors: Apostolakis, Stavros; Shantsila, Eduard; Lip, Gregory Y.H.

Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
pp. 797-806(10)
Authors: Vernon, John A.; Goldberg, Robert; Golec, Joseph

Budget-Impact Analyses: A Critical Review of Published Studies
pp. 807-827(21)
Authors: Orlewska, Ewa; Gulácsi, Laszlo

A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
pp. 829-846(18)
Authors: McCullagh, Laura; Tilson, Lesley; Walsh, Cathal; Barry, Michael

An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
pp. 847-859(13)
Authors: Benedict, Ágnes; Cameron, David A.; Corson, Hélène; Jones, Stephen E.

30 Years of Pharmaceutical Cost-Utility Analyses: Growth, Diversity and Methodological Improvement
pp. 861-872(12)
Authors: Neumann, Peter J.; Fang, Chi-Hui; Cohen, Joshua T.

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
pp. 873-886(14)
Authors: Liubao, Peng; Xiaomin, Wan; Chongqing, Tan; Karnon, Jon; Gannong, Chen; Jianhe, Li; Wei, Cui; Xia, Luo; Junhua, Cao